On June 18, Geelonghuiniu investors asked on the investor interactive platform of Chuanning Biology (301301.SZ), "How much is the company's expected synthetic biology related business revenue ratio for 2024?" The company replied that the synthetic biology project has already brought some revenue to the company, but the current revenue ratio is still relatively small. 2024 is a period of capacity climbing for the company's synthetic biology products, and the company will fully leverage existing advantages and continuously increase the revenue contribution of synthetic biology products to the company.
川宁生物(301301.SZ)：合成生物学项目目前已经为公司带来部分营业收入，但目前收入占比仍相对较小
Chuanning Biology (301301.SZ): The synthetic biology project has brought some revenue to the company, but the current revenue share is still relatively small.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.